Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Globe Newswire•12/11/2026•16:15 ET
0
Key Highlights
- ➤$340.9 million cash, equivalents, and securities; runway expected into mid-2028
- ➤NXC-201 posted 89% complete response across all 45 NEXICART-2 patients
- ➤BLA submission planned for mid-2027
- ➤$15.9 million third-quarter operating expenses
- ➤NEXICART-2 interim data selected for oral ASH 2026 presentation
— Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement —
— Interim NEXICART-2 clinical trial results selected for oral presentation at ASH 2026 —
Get started
Create a free account to read the full story.